2025
SK Life Science, Inc. Notice of 340B Price Adjustments for Select Products
Johnson and Johnson Notice Regarding Refunds to 340B Covered Entities - 1Q2022
Sumitomo Pharma Notice of 340B Price Changes
Merck Notice Regarding Refunds for 340B Purchases for 1Q22
Eisai Notice Regarding Offer to Refunds for 3Q23 and 4Q23
GSK Notice Regarding 3Q23 340B Price Adjustment
GSK Notice Regarding 1Q23 340B Price Adjustment
Dr. Reddy's Notice Regarding Naloxone NDCs
Amgen Notice Regarding Repatha NDCs
Dr. Reddy's Notice Regarding Fulvestrant NDC Change
Organon Notice Regarding Ganirelix NDC Update
CooperSurgical Notice regarding NDC change for Paragard
Evofem Notice Regarding NDC Change for Solosec
GSK Notice Regarding Adjustment to 340B Prices for 4Q22
AbbVie Notice of Price Adjustment Regarding Purchases of Norvir
Eli Lilly Notice Regarding Changes to 1Q22 340B Ceiling Prices
Xellia Notification of 340B Price Adjustments for Select Products
Notice to Covered Entities Regarding TRUQAP NDCs
Ascend Laboratories Notice Regarding Offer of 340B Refunds
Amgen Notice Regarding Prolia NDCs
Amgen Notice of Refunds to 340B Covered Entities 3Q21 – 4Q21
Eli Lilly Notice of Q421 340B Price Changes
Amgen Notice Regarding Evenity NDCs
Merck Notice Regarding Offer of Refunds to 340B Covered Entities
Kedrion Biopharma Inc. Notice Regarding Offer of Refunds
GSK Notice Regarding Adjustment to 340B Prices for 3Q22
Mylan Institutional Triamcinolone Acetonide NDC Change Notice
SK Life Science Notice Regarding 340B Price Adjustments for Select Products
Pfizer Notice of NDC Replacements for 340B Replenishment
Apotex Corp. Notice Regarding Refunds to 340B Covered Entities
Lilly Notice of Changes to 340B Prices Q2 2021
RedHill Notice Regarding Offer of Refunds to 340B Covered Entities
Valinor Notice Regarding Offer of Refunds to 340B Entities
Merck Notice to Regarding Offer of 340B Refunds
Alnylam Notice Regarding Adjustments to 340B Prices
WG CriticalCare Notice to Covered Entities Regarding Refunds
Novo Nordisk Notice Regarding Adjustments of 340B Prices on Select Products
Cosette Pharmaceuticals Notice to 340B Covered Entities
Takeda Notice Regarding Refunds to 340B Covered Entities
Novartis Notice of Refunds to 340B Covered Entities
Amgen Notice Regarding Refunds to 340B Covered Entities Q1-Q2 2021
J&J Notice Regarding 1Q21 Refunds to Covered Entities
Grifols Notice Regarding HyperRHO Replenishment
Biocon IG-yfgn Semglee Notice of NDC change
Biocon Semglee Vials Notice of NDC change
Genentech Notice of Refunds for Perjeta
Genentech Notice of Refunds for Klonopin
Merck Notice Regarding Refunds to 340B Covered Entities 1Q21
GSK Notice Regarding Adjustment to 340B Prices for 2Q22
Vertex Notice Regarding Adjustment of 340B Prices
GSK Notice Regarding Adjustment of 340B Prices for Selected Products
Johnson & Johnson Notice Regarding Refunds to 340B Covered Entities
Amgen Updated Notice Regarding Availability of Certain Kanjinti NDCs
Grifols Notice Regarding Albutein Replenishment
Novo Nordisk Notice Regarding 4Q23 340B Price Adjustment for Select Products
Novo Nordisk Notice Regarding 340B Price Adjustments for Select Products
SpecGx LLC Recalculated 340B ceiling prices for certain products for 3Q20–1Q23
Notice Regarding 340B Price Adjustment for Select Jazz Pharmaceutical Products
GSK Notice Regarding Adjustment of 340B Prices for Selected Products 4Q21
Biocon Biologics NDC Change and Replenishment for Insulin Glargine-YFGN
Biocon Notice of NDC Change and Replenishment for OGIVRI/FULPHILA
Granules Pharmaceuticals Notice of Refunds Q4 2021 to Q2 2023
Noven Recalculated Ceiling Price Notice to Covered Entities
Novartis Notice Regarding Locametz and Netspot
Eli Lilly Notice Regarding Price Changes
Novo Nordisk Notice Regarding Price Adjustments
Amgen Notice Regarding Availability of Certain Kanjinti NDCs
Novo Nordisk Notice of refunds 1Q-2Q 2023 Ozempic
WG Critical Care Notice of Refunds 2Q 2022
Merck Notice of Refunds to Covered Entities 3Q 2020
Johnson & Johnson Notice of Refunds to Covered Entities 3Q2020
Tolmar Notice of Refunds 4Q2017 to 4Q2022
Purdue Notice of 340B Price Changes
Meitheal Notice Regarding 340B Refunds
GSK Notice of Refunds to Covered Entities Q3 2021
Amgen Notice Regarding Refunds to 340B Covered Entities Q3 2020 – Q4 2020
Vertex Pharma Notice of Refunds to Covered Entities 4Q2022 to Q2 2023
Notice to 340B covered entities regarding ANDEXXA replenishment
Amring Refund Notice to 340B Covered Entities
VistaPharm Notice Regarding Recalculated 340B Ceiling Prices
Eli Lilly and Company Notice of Refunds to Covered Entities 3Q 2020
Novo Nordisk Inc. Notice of Refunds to Covered Entities Q3 2020
Neurocrine Notice Regarding Offer of Refunds to 340B Covered Entities for 3Q2022 – 2Q2023
Amneal Notice Regarding Lioresal Intrathecal Baclofen NDC Change and Replenishment
Merck Notice of Refunds to Covered Entities Q2 2020
SK Life Sciences Notice of Refunds to Covered Entities Q3 2021 through Q2 2022
Merck Notice of Refunds to Covered Entities Q1 2020
Amgen Notice of Refunds to Covered Entities Q1-Q2 2020
GSK Notice of Refunds to Covered Entities Q2 2021
Johnson and Johnson Notice Regarding Refunds to 340B Covered Entities
Chartwell Rx LLC Notice of Refunds to Covered Entities Q4 2022
Lifestar Pharma Notice of Refunds to Covered Entities Q4 2022
Astellas Notice Regarding Cresemba NDC Change and Replenishment
Daiichi Sankyo, Inc Notice to Regarding Refunds for Certain Products
Dermavant Sciences Inc. Notice of Refunds to Covered Entities for 2Q 2022 – 1Q 2023
Viatris Notice Regarding NDC Changes
Amneal Notice of Refunds to Covered Entities 3Q 2019-3Q 2022
Zydus Pharmaceuticals Notice of Refunds to Covered Entities 1Q 2022-3Q 2022
GSK Notice Regarding Adjustment of 340B Price
Astellas Notice Regarding Cresemba NDC Change
J&J Notice Regarding Refunds to Covered Entities
Alcon Laboratories, Inc. Notice Regarding Refunds to 340B Covered Entities
2022
Viatris Notice of Ceiling Price Correction Period
Merck Products Notice - Offer of Refunds Multiple quarters 4Q 2019 to 2Q 2022
Novo Nordisk Inc. Notice Regarding Adjustment of 340B Prices for Select Products
Lilly Notice of Changes to 340B Prices for 1Q 2022
Astra Zeneca Notice Regarding Calquence Replenishment
Purdue Pharma L.P. Notice of Refunds Q1 2020 and Q2 2020 for Select Products
GSK Notice of Refunds for 4Q 2020 for Select Products
Amgen Notice Regarding Refunds to 340B Covered Entities
Merck Products Notice of Refunds Offer Q3 2019
GSK Notice to Covered Entities of Price Adjustment Select Products Q3 2020
Strides Pharma Inc. Notice of Potential 340B Refunds
Eli Lilly Notice of Changes to 2nd Quarter 2019 340B Ceiling Prices
Novo Nordisk Inc. Notice Regarding Adjustment of 340B Prices for Select Products
e5 Pharma Notice of Offer of Refunds
BMS Notice regarding 340B Price Adjustments
MNK Spec GX Notice of Recalculated 340B Ceiling Prices
GSK Notice Regarding Offer of Refunds to 340B Covered Entities
Amgen Notice Regarding Refunds to 340B Covered Entities
Astellas Notice of Recalculated 340B Ceiling Prices 3Q21-2Q22
BioComp Notice to Covered Entities
BMS Refund to 340B Covered Entities
Eli Lilly Notice of Changes to 3rd Quarter 2019 340B Ceiling Prices
Kala Notice to Refund Covered Entities
J&J Notice of Refunds for Q3 and Q4 2019
Eli Lilly Notice of Changes to Second Quarter 2019 340B Prices
GSK Notice Regarding Offer of Refunds to 340B Covered Entities
Notice of Adjustment to 340B Price for Vertex Pharmaceuticals' Trikafta®
NovoNordisk Notice of Refunds to 340B Covered Entities
BMS Notice to Covered Entities of Refunds to 340B Covered Entities
Notice of Partial Refund Ipsen's Somatuline® Depot
2021
Eli Lilly Notice of Changes to First Quarter 2019 340B Prices
GSK Notice of Refunds to 340B Covered Entities
Exelan Notice of Refunds to 340B Covered Entities
BioMarin Notice of Refunds to 340B Covered Entities Q4 2020 - Q1 2021
Notification of Supply Allocation: Vidaza (azacitidine)
Johnson and Johnson Notice Regarding Refunds to 340B Covered Entities
Mytesi Notice of Distribution Network
Notification of Global Shortage of Actemra IV (tocilizumab)
BioMarin - Notice of Refund to 340B Covered Entities Q1 2019 – Q4 2020
Notice of Limited Distribution for Pegcetacoplan
Novartis Notice of 340B Price Adjustment
Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc
Updated Notice Regarding Limited Distribution Plan for AYVAKIT (avapritinib)
Purdue Notification to Covered Entities of Price Recalculations
SpecGX LLC (Mallinckrodt) Notice to Covered Entities of Price Recalculations
Verity Notice to Covered Entities of Continuation of Limited Distribution Plan for TRELSTAR
Chartwell RX LLC Notice to Covered Entities of Price Recalculations
Notice Regarding Adjustment of 340B Prices for Select Products of Xellia Pharmaceuticals (US) LLC
Takeda Notification of Updated Limited Distribution Plan for Iclusig
Civica Notice to Covered Entities of Price Recalculation
340B Distribution Notice for Nulibry™
Pharmaceutical Associates Inc. Notice to Covered Entities of Price Recalculations
Esperion Notice to Covered Entities of Price Recalculations
GSK Notice to Covered Entities of Price Recalculations
Beach Products Inc. Labeler 00486 Recalculation K Phos
eTon Pharmaceuticals Notice of Limited Distribution Plan for ALKINDI SPRINKLE
2020
Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma Inc.
Purdue Notice to Covered Entities of Price Changes for Labeler 59011/67618
UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use)
REVISED Notice to 340B Covered Entities Regarding BALVERSA® Limited Distribution Plan
Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc.
Limited Distribution Notice for EVRYSDI (risdiplam)
Notice to 340B Covered Entities Regarding Uplizna™ (inebilizumab-cdon) Limited Distribution Network
Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc.
Notice Regarding Offer of Refunds to 340B Covered Entities for Purchases of NuvaRing®
Notice to 340B Covered Entities: Zestril® Limited Distribution
Sunovion Pharmaceuticals, Inc. Limited Distribution Network for KYNMOBI™
Notice to 340B Covered Entities Regarding PALYNZIQ™
Notice on Otezla Replacement NDCs
Taiho Oncology Inc. Notice of Limited Distribution Network
Limited Distribution Notice for Opsumit, Tracleer, Uptravi, Veletri, Ventavis, and Zavesca
Limited Distribution Plan Notice for Cialis® (tadalafil) Erectile Dysfunction NDCs
Notice Regarding Limited Distribution Network for Nourianz (Istradefylline)
Alternative Distribution Plan for Certain Bausch Health NDCs and Notice of Covered Entity Refunds
Incyte Limited Distribution Network for Pemazyre
Incyte Updated Defined Distribution Network for Jakafi
Notice Regarding Adjustment of 340B Prices for Select Products of Lupin Pharmaceuticals Inc.
Notice of Distribution Model for Qinlock™
UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use)
Notice of Price Adjustment to PHS Covered Entities
Removal of Program Astagraf Limited Distribution Plan
Bayer Healthcare Limited Distribution Plan for Adempas
Limited Distribution Network for DOPTELET® (avatrombopag) Updated 2020
Vertex Pharmaceuticals Inc. Notice of Limited Distribution Plan
Notice for Resticted Distribution Network for Sublocade
Exelixis Notice of Distribution Model for Cabometyx
Notice Regarding Repatha Replacement
Updated Notice of Distribution Model for Cometriq
Notice of Change in Distribution Model for TYMLOS®
Notice Regarding Recalculated 340B ceiling prices for Apotex Corp
Distribution Plan for certain generic products for Bausch Health
Limited Distribution Notice for NUPLAZID® (pimavanserin) Tablets and Capsules
Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc.
Notice of Change in Distribution Model for Kitabis™ Pak (NDC 24492-850-56)
Notice to 340B Covered Entities Regarding Replacement NDCS For Enbrel®
2019
Notice to 340B Covered Entities That Purchased Xspire Products
340B Limited Distribution Notice for Corlanor® (ivabradine) Oral Solution 5 mg (NDC 55513-0813-28)
Notice of Change in Distribution Model for Adrenalin and Vasostrict
Notice to 340B Covered Entities Regarding Calcium Acetate (Generic) Capsules
Updated 340B Limited Distribution Notice for Xermelo
340B Notice Regarding Updated Limited Distribution Plan for Nulojix (belatacept)
Daiichi Sankyo Notice to 340B Covered Entities Regarding Turalio™
Notice to 340B Covered Entities Related to Axumin™ (NDC # 69932-0001-01)
Notice to Covered Entities Regarding Balversa Limited Distribution Plan
340B Limited Distribution Notice for OXERVATE (NDC 71981-0020-01)
Notice Regarding Recalculated 340B Price for Amphastar Pharmaceuticals, Inc.
Notice Regarding Recalculated 340B Ceiling Prices for The Medicines Company Products
Notice Regarding Adjustment of 340B Prices for Purdue Pharma L.P.
Millennium Pharmaceuticals Notice Regarding Adjustment of 340B Prices for Velcade
Vifor Mircera Notice of End of Limited Distribution Plan
Catalyst FIRDAPSE® (amifampridine) tablets Notice Regarding Limited Distribution Plan
Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma, Inc.
Notice Regarding Recalculated 340B Prices for Sebela Products
Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P.
NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG (BCG LIVE for intravesical use)
Insmed Limited Distribution Plan for ARIKAYCE
2018
Biovertiv Replenishment Notice to Covered Entities for Alprolix and Elocate
Akorn Notice to covered entities potential overcharge Methylene Blue 1% 10ml
Agios TIBSOVO® Limited Distribution Plan
Recalculated 340B Ceiling Prices for Lilly Products
Valeant potential overcharge letter labeler 16781 NDC's
Notice Regarding Recalculated 340B Ceiling Prices for Genentech Product
Shire 340B Ceiling Price Recalculation Notice
2017
Almatica Pharma-Tenormin Limited Distribution Plan
Johnson and Johnson Healthcare Systems Inc. Notice regarding 340B Ceiling Prices for 1Q2017
Notice Regarding Pfizer Defined Oncology Distribution Network
2016
Notice Regarding 340B Pricing for Millennium Pharmaceuticals VELCADE
Notice Regarding 340B Pricing for BiCNU
UPDATE Notice to 340B Covered Entities Regarding Baxalta's VONVENDI
340B Notice Regarding Limited Distribution Plan for Imbruvica (ibrutinib)
Notice to 340B Covered Entities Regarding 340B Ceiling Prices for Ascend Products
2015: Notice Regarding Limited Distribution Network for Reylimid, Pomalyst and Thalomid
2014: Bayer Limited Distribution System for Betaseron
2013: Bayer Skyla Letter 05/31/2013
2009: Limitations on Sales of Venofer® 10/29/2009
Accessibility
If you use assistive technology, you may not be able to fully access information in these files. For assistance, please email 340B-Communication@hrsa.gov.